Try our beta test site
74 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND anti-cd19 [TREATMENT]
Show Display Options
Rank Status Study
1 Not yet recruiting Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Anti-CD19-CAR γδT
2 Recruiting Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Condition: B-cell Lymphomas
Intervention: Genetic: Anti-CD19 CAR T cells
3 Not yet recruiting Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Anti-CD19-CAR
4 Recruiting Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Biological: autologous anti-CD19 CAR T cells
5 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Lymphoma
Intervention: Combination Product: Drugs and Anti-CD19-CAR transduced T cells
6 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   Non-hodgkin Lymphoma,B Cell;   Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
7 Terminated CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
Condition: Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
Intervention: Biological: RNA anti-CD19 CAR T cells
8 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Condition: LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Intervention: Biological: CART 19
9 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia;   Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR transduced T cells
10 Unknown  Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: MOR00208 (formerly Xmab 5574)
11 Active, not recruiting the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
Condition: Lymphoma, Large B-Cell, Diffuse
Intervention: Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
12 Not yet recruiting Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
Condition: Lymphoma, B Cell
Interventions: Biological: IL-2 pre-treated CD19 cells;   Biological: IL-7/IL-15 pre-treated CD19 cells
13 Active, not recruiting CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Conditions: Primary Mediastinal B-cell Lymphoma;   Diffuse, Large B-cell Lymphoma;   Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma;   Mantle Cell
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR PBL
14 Active, not recruiting Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Conditions: ALL;   B Cell Lymphoma;   Leukemia;   Large Cell Lymphoma;   Non-Hodgkin Lymphoma
Intervention: Biological: Anti-CD19- CAR
15 Recruiting A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects
Condition: Refractory Diffuse Large B-Cell Lymphoma
Intervention: Biological: C-CAR-011
16 Recruiting Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Conditions: Acute Lymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: huCART19
17 Recruiting Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Condition: Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Intervention: Biological: CART-19
18 Recruiting T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
Conditions: Acute Lymphoblastic Leukemia, B-precursor;   Non-Hodgkin Lymphoma, B-cell
Intervention: Biological: CD19 CAR T cells
19 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
20 Recruiting Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Conditions: CD19+ Diffuse Large B-cell Lymphomas;   Follicular Lymphomas;   Mantle Cell Lymphomas
Intervention: Drug: Pembrolizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.